The Innovation at a Glance
Patent US11571480B2, assigned to Coherent Biopharma Ltd, discloses multi-ligand drug conjugates designed to deliver therapeutic payloads more effectively. The invention involves conjugates comprising two or more types of cell-interacting molecules that specifically bind to cell surface receptors. By utilizing multiple ligands, these drug conjugates aim to enhance targeting precision and payload delivery efficiency, which are critical factors in treating diseases that require sophisticated therapeutic intervention.
The Inventor & Company Behind It
Coherent Biopharma Ltd is the assignee of this advanced patent in the HealthTech domain. The company focuses on biotechnological innovations that address unmet medical needs through novel drug delivery mechanisms. This patent exemplifies Coherent Biopharma’s strategic emphasis on refining molecular targeting techniques to improve treatment specificity and efficacy.
Market Opportunity
The technology targets the burgeoning market for targeted therapeutics, which continues to grow driven by demand for personalized medicine and biologics. Multi-ligand conjugates have the potential to substantially improve clinical outcomes by enhancing drug specificity and reducing off-target effects. While still awaiting clinical validation, this approach aligns well with industry trends favoring complex biologic therapies over traditional small-molecule drugs.
Growth Indicators
Notably, US11571480B2 has amassed 289 citations, indicating significant recognition and influence within the scientific and patent communities. The HIS score of 73.9 underscores its technological importance and commercial relevance in HealthTech. These metrics suggest the invention is positioned as a foundational asset within the field of targeted drug delivery, attracting considerable interest from competitors and collaborators alike.
Why IP Investors Are Watching
Investors are closely monitoring this patent due to its potential to underpin next-generation targeted therapies that could capture meaningful market share. The multi-ligand approach addresses key limitations of single-ligand delivery systems, offering a competitive edge. However, productization depends on successful clinical and regulatory progress, which will be critical for translating the patented technology into licensable or commercial products. The patent’s global health implications further enhance its strategic value within an increasingly crowded and competitive biotech landscape.
Get the Full Analysis
For a comprehensive assessment of how US11571480B2 fits into the evolving domain of targeted therapeutics and what it might mean for Coherent Biopharma Ltd's IP portfolio and investment potential, consult the detailed reports available on IPI Terminal. Our patented HIS scoring and citation analysis provide investors a data-driven basis to gauge this asset’s long-term prospects.